Press Releases May 15, 2026 08:30 AM

SRx Health Solutions Announces Board Approval to Dividend 75% of Profits from Investment in Astro Investment XVII, an Affiliate of Astro Capital and SPV with Investments in SpaceX and Other Artificial Intelligence and Space Companies

SRx Health Solutions to dividend majority of profits from strategic investment in AI and space-focused Astro Investment XVII

By Avery Klein SRXH

SRx Health Solutions announced that its board has approved a dividend distribution of 75% of profits from its investment in Astro Investment XVII, an affiliate of Astro Capital. This investment includes holdings in SpaceX and other artificial intelligence and space technology companies. The move reflects SRx Health Solutions' confidence in the long-term growth potential of AI and space sectors and provides an opportunity for shareholder returns following the wind down of the special purpose vehicle (SPV).

SRx Health Solutions Announces Board Approval to Dividend 75% of Profits from Investment in Astro Investment XVII, an Affiliate of Astro Capital and SPV with Investments in SpaceX and Other Artificial Intelligence and Space Companies
SRXH

Key Points

  • SRx Health Solutions holds over 10% investable capital in Astro Investment XVII, which invests in AI and space companies including SpaceX.
  • The board approved a dividend of 75% of profits from this investment to be paid to shareholders upon the SPV's wind down.
  • The investment strategy reflects an interest in high-growth technology sectors—artificial intelligence and space exploration.
  • Sectors impacted include technology (AI and aerospace), investment management, and healthcare markets due to cross-sector investment activities.

NORTH PALM BEACH, Fla., May 15, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive merger agreement, today announced board approval to dividend 75% of profits from investment in Astro Investment XVII, an affiliate of Astro Capital and special purpose vehicle (SPV), with investments in SpaceX and other artificial intelligence and space companies.

The Company recently announced an investment of greater than 10% of its investable capital in Astro Investment XVII and will return capital to shareholders upon wind down of the SPV.

For more information please visit, Astro Capital.

“This investment demonstrates our belief in the long-term value of both AI and space,” said Michael Young, Board Member of SRx Health. “Our investment in EMJX and Astro Capital provides an avenue to invest in these high potential growth areas through technology and professional managers. With board approval to issue a dividend upon wind down the SPV and profit in the investment, we are excited about the opportunities this potential will present for our shareholders.”

Additional Information and Where to Find It
In connection with the proposed transaction between the Company has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the common stock to be issued in connection with the proposed transaction. The Registration Statement includes an information statement of the Company and a prospectus of the Company (the "Information Statement/Prospectus"), and each of EMJX and the Company may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Information Statement/Prospectus will be sent to the stockholders This is not a substitute for the Registration Statement, the Information Statement/Prospectus or any other relevant documents that EMJX or the Company has filed or will file with the SEC. BEFORE MAKING ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EMJX, THE COMPANY, THE PROPOSED TRANSACTION, AND RELATED MATTERS. A copy of the Registration Statement, Information Statement/Prospectus, as well as other relevant documents filed by EMJX and the Company with the SEC, may be obtained free of charge, when they become available, at the SEC's website at www.sec.gov. The information on EMJX's or the Company's respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

Company Contact
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
[email protected]


Risks

  • Completion of the proposed merger with EMJ Crypto Technologies (EMJX) is subject to shareholder approval and market conditions.
  • Returns depend on the performance and timing of the wind down of the SPV, which is uncertain and could affect dividend payments.
  • Regulatory and market risks related to investments in emerging technologies such as AI and space exploration could impact financial results.

More from Press Releases

nVent Announces Share Repurchase Authorization May 16, 2026 nVent Announces Quarterly Cash Dividend May 16, 2026 Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma May 15, 2026 Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update May 15, 2026 Skeena Gold & Silver Reports Q1 2026 Financial Results May 15, 2026